REG - AstraZeneca PLC - AstraZeneca completes Cellectis equity investment

AstraZenecaAnnouncement

07/05/2024 07:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240507:nRSG2725Na&default-theme=true

RNS Number : 2725N  AstraZeneca PLC  07 May 2024

7 May 2024

AstraZeneca completes equity investment agreement with Cellectis

 

AstraZeneca today announced the successful completion of an equity investment
with Cellectis, a clinical-stage biotechnology company.

 

The equity investment and a research collaboration agreement, announced in
November 2023
(https://www.astrazeneca.com/media-centre/press-releases/2023/astrazeneca-cell-and-gene-therapy-deal-w-cellectis.html)
will leverage the Cellectis proprietary gene editing technologies and
manufacturing capabilities, to design up to 10 novel cell and gene therapy
products for areas of high unmet need, including oncology, immunology and rare
diseases.

 

Financial considerations

In Q4 2023, Cellectis received an initial payment of $105m from AstraZeneca,
which comprised a $25m upfront cash payment under the terms of a research
collaboration agreement and an $80m equity investment.

 

An additional $140m equity investment, at $5/share, has closed following the
satisfaction of customary closing conditions including Cellectis shareholders'
approval and regulatory clearances. Post-closing of this second investment,
AstraZeneca holds a total equity stake of c.44% in Cellectis. AstraZeneca
expects to continue to treat its investment in Cellectis as an associate.

 

Under the terms of the research collaboration, Cellectis is also eligible to
receive an investigational new drug (IND) option fee and development,
regulatory and sales-related milestone payments, ranging from $70m up to
$220m, per each of the 10 candidate products, plus tiered royalties.

 

AstraZeneca retains an option for a worldwide exclusive license for the
candidate products developed under the research collaboration agreement, to be
exercised before IND filing.

Notes

 

Alexion

Alexion, AstraZeneca Rare Disease is focused on serving patients and families
affected by rare diseases and devastating conditions through the discovery,
development and delivery of life-changing medicines. A pioneering leader in
rare disease for more than three decades, Alexion was the first to translate
the complex biology of the complement system into transformative medicines,
and today it continues to build a diversified pipeline across disease areas
with significant unmet need, using an array of innovative modalities. As part
of AstraZeneca, Alexion is continually expanding its global geographic
footprint to serve more rare disease patients around the world. It is
headquartered in Boston, US.

 

AstraZeneca in oncology
(https://www.astrazeneca.com/our-therapy-areas/oncology.html)

AstraZeneca is leading a revolution in oncology with the ambition to provide
cures for cancer in every form, following the science to understand cancer and
all its complexities to discover, develop and deliver life-changing medicines
to patients.

 

The Company's focus is on some of the most challenging cancers. It is through
persistent innovation that AstraZeneca has built one of the most diverse
portfolios and pipelines in the industry, with the potential to catalyse
changes in the practice of medicine and transform the patient experience.

 

AstraZeneca has the vision to redefine cancer care and, one day, eliminate
cancer as a cause of death.

 

AstraZeneca (https://www.astrazeneca.com/)

AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, and Respiratory &
Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries
and its innovative medicines are used by millions of patients worldwide.
Please visit astrazeneca.com (http://www.astrazeneca.com/)  and follow the
Company on social media @AstraZeneca
(https://gateway.zscalertwo.net/auD?origurl=https:%2f%2fwww.linkedin.com%2fcompany%2fastrazeneca&_ordtok=Mkk3WV5DBDPmQrD4F5MGdGDMZR)

 

Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFLFELEVIEIIS